{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '8.1.9.2.', '8.1.9.3.', '53', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '9. Data Monitoring and Adverse Event Reporting Requirements', 'Institutional support of trial monitoring at the University of Washington/Seattle Cancer Care', 'Alliance study site will be in accordance with the FHCRC/University of Washington Cancer', 'Consortium Institutional Data and Safety Monitoring Plan. Under the provisions of this plan,', 'FHCRC Clinical Research Support coordinates data and compliance monitoring conducted', 'by consultants, contract research organizations, or FHCRC employees unaffiliated with the', 'conduct of the study. Independent monitoring visits occur at specified intervals determined', 'by the assessed risk level of the study and the findings of previous visits per the institutional', 'DSMP.', 'In addition, protocols are reviewed at least annually and as needed by the Consortium Data', 'and Safety Monitoring Committee (DSMC), FHCRC Scientific Review Committee (SRC) and', 'the FHCRC/University of Washington Cancer Consortium Institutional Review Board (IRB).', 'The review committees evaluate accrual, adverse events, stopping rules, and adherence to', 'the applicable data and safety monitoring plan for studies actively enrolling or treating', 'patients. The IRB reviews the study progress and safety information to assess continued', 'acceptability of the risk-benefit ratio for human subjects. Approval of committees as', 'applicable is necessary to continue the study.', 'The trial will comply with the standard guidelines set forth by these regulatory committees', 'and other institutional, state and federal guidelines.', 'Additionally, scheduled meetings will take place weekly and will include the protocol', 'Principal Investigator (PI) (Michael Schweizer, MD), and when appropriate, the', 'collaborators, sub-investigators, and biostatistician involved with the conduct of the protocol.', 'During these meetings the investigators will discuss matters related to: safety of protocol', 'participants, validity and integrity of the data, enrollment rate relative to expectation,', 'characteristics of participants, retention of participants, adherence to protocol (potential or', 'real protocol violations), data completeness, and progress of data for secondary objectives.', 'External monitoring of participating sites will occur at least once per year, depending on the', 'rate of accrual at these sites.', '54', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '9.1. Management of Safety Data', 'This study has been designated as an interventional study. As such, all adverse events', 'regardless of causality and special situations excluding those from subjects not', 'exposed to apalutamide and product quality complaints with or without an adverse', 'event as described in this clinical protocol will be reported from the time a subject has', \"signed and dated an Informed Consent Form (ICF) until completion of the subject's last\", 'study-related procedure (which may include contact for follow-up safety). Serious', 'adverse events will be reported for 30 days after the last dose of study drug.', '9.2. Definitions', '55', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}